Diaverum, a leading global renal care service provider, is pleased to announce that, effective 25 January 2022, it has taken control of the business and daily management of the Ningguo, Wuhu, Liangxi and Xishan clinics, further expanding its presence in China and the Far East.
The move comes following the reaching of an agreement in recent days with Diaverum's partners in China, Nanjing Chengqi Medical Products Co., Ltd. Both Diaverum and its JV partner recognise the importance of delivering a smooth transition of ownership to ensure operational continuity in the clinics and are therefore working together to fulfil such commitment. In total, Diaverum will now be operating 7 clinics in China, with 122 staff treating 205 patients.
Commenting on the news, Sophia Zhang, Managing Director for Diaverum China, said: “It is with great satisfaction that we welcome these clinics to the Diaverum family, a company that provides world-class, life-enhancing renal care and empowers patients to live fulfilling lives. Looking ahead to 2022 and beyond, it is an exciting time to be part of Diaverum. We have embarked on an ambitious journey to become the global renal care provider of choice in the next few years; China, and the teams working here, will be instrumental in fulfilling this ambition”.
Denis Ding, HR Director for Diaverum China, added: “At Diaverum, our first priority is always our patients and we are absolutely committed to ensuring seamless treatment continuity for all of them during this transition period. That’s why we are assigning medical, operations and supporting teams to each of the clinics to work closely with our teams on site, with immediate effect”.